Mylan buying Perrigo – Broadening Product Range & Extending Geographic Reach – Reuters

The deal in 4 points

MoneyUSD 29 billion in cash and stock spent.

25% premium over the last closing price.

USD 15.3 billion of pro-forma combined sales in 2014.

Would be the biggest health care deal year to date, ahead of AbbVie-Pharmacyclics (USD 21bn) and Pfizer-Hospira (USD 16.7bn).

Reuters Article

Image Source

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s